Latest News

  • Free Webinar on "Prefilled Syringe Elastomer Components - High-quality Solutions for Sensitive Molecules
    Webinar information:Join the experts on this free exclusive webinar on the 16th July 2020 at 2pm BST, hosted by West Pharmaceutical Services, Inc. As the industry continues to see significant growth for drug products developed in prefilled syringe systems (PFS), there is a trend for pharmaceutical companies to evaluate more complex drug molecules, such as biologics.This webinar discusses current trends in the market for injectable drug delivery and outlines current challenges for companies developing drug products in a prefillable syringe system.
  • CARTANA launches expanded range of In Situ Sequencing kits for high throughput single cell gene expression mapping
    Stockholm, May 1st, 2020 – Swedish biotechnology company CARTANA today announced the launch of a new range of In Situ Sequencing (ISS) reagent kits designed to increase the efficiency and enable ISS on virtually any tissue sample. Users will be able to analyse either fresh/fixed frozen or FFPE samples and rapidly create single cell gene expression maps of up to 600 genes.
  • Avacta Ships SARS-COV-2 Affimer Reagents to Cytiva and Adeptrix
    Cambridge and Wetherby, UK, 11 May 2020: Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.
  • Imperial College London researchers join forces with Intelligent Fingerprinting to develop 10-minute fingerprint test for COVID-19
    Fingerprint testing provides results in 10 minutes, with no need for medical staff.Portable and non-invasive, fingerprint-based method is ideal for on-site testing in care homes and the workplace
  • Volition Files Patent for Nu.QTM COVID-19 Triage Test and Commences Proof of Concept Studies
    AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more